NCT02224664 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Parkinson's Disease

Interventions

DRUG

PF-06649751

Oral daily doses titrated up to 5mg QD

DRUG

PF-06649751

Oral daily doses titrated up to 15 mg QD

DRUG

PF-06649751

Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)

DRUG

PF-06649751

Oral daily doses titrated up to 25 mg QD

Trial Locations (17)

27612

Carolina Phase I Research, LLC, Raleigh

30331

Atlanta Center for Medical Research, Atlanta

32806

Compass Research, LLC, Orlando

33009

MD Clinical, Hallandale

48334

Quest Research Institute, Farmington Hills

73112

Lynn Health Science Institute, Oklahoma City

75231

Neurology Consultants of Dallas, PA, Dallas

Walnut Hill Medical Center, Dallas

80113

Rocky Mountain Movement Disorders Center, Englewood

80228

Davita Clinical Research Center, Lakewood

90806

Collaborative Neuroscience Network, LLC, Long Beach

92708

Orange Coast Memorial Medical Center, Fountain Valley

The Parkinson's and Movement Disorder Institute, Fountain Valley

02114

Massachusetts General Hospital -- FOR DRUG SHIPMENT ONLY, Boston

Massachusetts General Hospital, Boston

08053

PRA International, Marlton

B-1070

Pfizer Clinical Research Unit, Brussels